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Abstract
Many mitosis inhibitors are powerful anticancer drugs. Tremendous efforts have been made to identify new anti-mitosis
compounds for developing more effective and less toxic anti-cancer drugs. We have identified LJK-11, a synthetic analog of
5, 8-disubstituted quinazolines, as a novel mitotic blocker. LJK-11 inhibited growth and induced apoptosis of many different
types of tumor cells. It prevented mitotic spindle formation and arrested cells at early phase of mitosis. Detailed in vitro
analysis demonstrated that LJK-11 inhibited microtubule polymerization. In addition, LJK-11 had synergistic effect with
another microtubule inhibitor colchicine on blocking mitosis, but not with vinblastine or nocodazole. Therefore, LJK-11
represents a novel anti-microtubule structure. Understanding the function and mechanism of LJK-11 will help us to better
understand the action of anti-microtubule agents and to design better anti-cancer drugs.
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Introduction
Microtubules are critical elements in a variety of fundamental
cellular functions, including formation and maintenance of cell
shape, transportation of vesicles and protein complexes, and
regulation of motility and cell division[1]. Microtubules are
extremely important in the process of mitosis, during which the
duplicated chromosomes of a cell are separated into two identical
sets before cleavage of the cell into two daughter cells. The
essential role of microtubules in mitosis and cell division makes
them and their regulatory proteins important, perhaps the best,
targets for anticancer drugs.Anti-microtubule agents, such as
nocodazole, vinorelbine, colchicines, and paclitaxel, bind micro-
tubules, deregulate microtubule dynamics, activate mitotic spindle
checkpoint, and induce cell apoptosis[2–4]. Many studies have
confirmed that suppression of microtubule dynamics and inter-
ference of microtubule polymerization or depolymerization seems
to be an effective why to block mitosis and kill tumor cells[5,6].
The anti-microtubule agents have been successfully used in
treating a variety of cancers[7,8].
Microtubule-targeted anti-mitotic drugs are usually classified into
two main groups based on their mode of action. One group, known
as microtubule-destabilizing agents, inhibits microtubule polymeri-
zation and promotes microtubule depolymerization, such as vinca
alkaloids. The second group, represented by taxanes and character-
ized as microtubule-stabilizing agents, inhibits microtubule depoly-
merization and stabilizes microtubules. They are also classified based
on their binding sites on tubulin[8–10]. The anti-microtubule agents
affect microtubule-polymer mass as well as their dynamics. The
effects on microtubule dynamics are often more powerful than the
effects on polymer mass in treating cancer cells[11–13].
Although all of the anti-microtubule agents inhibit microtubule
dynamics in vitro effectively, their effects against different types of
cancers in vivo vary [14]. In addition, despite the success of
taxanes and vinca alkaloids to inhibit the progression of some
cancers in clinical use, resistance to anti-microtubule agents is
encountered in many tumor types, particularly during multiple
cycles of therapy[15–18]. Therefore, there has been great interest
in identifying and developing novel anti-microtubule drugs.
We have screened for growth inhibitory compounds and identified
LJK-11, an analog of 5, 8-disubstituted quinazolines, as a cell mitosis
blocker. Analysis of the function and mechanism of LJK-11 revealed
that LJK-11 is a microtubule- destabilizing agent. It inhibits
microtubule polymerization, arrests cells at early stage of mitosis,
and induces apoptosis. Our data suggest that LJK-11 is a novel anti-
microtubule compound. Understanding the mechanism of the LJK-
11 will increaseour knowledge about the anti-microtubuleagents and
will help us to design better anti-cancer drugs.
Results
LJK-11 inhibited growth and induced apoptosis of
human tumor cells
LJK-11 was synthesized as an analog of 5, 8-disubstituted
quinazolines (Fig. 1). The chemical formula of LJK-11 is C15H12N4O4
yielding a molecular weight of 312.28. Quinazolines are a class
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activities. Among them, 4-anilinoquinazolines are the most
promising small molecule EGFR tyrosine kinase inhibitors. The
5-substituted quinazoline derivatives, however, have no effect
on the EGFR tyrosine kinase, but display potent antiprolifer-
ative effect[19,20].
To understand the mechanism of the 5-substituted quinazoline
derivatives in inhibiting cell growth, we analyzed the effect of the
5-substituted quinazoline derivatives on the growth of a human
lung adenocarcinoma cell line A549 and identified LJK-11 as the
most effective compound. The growth of the A549 cells was
inhibited by LJK-11 in a dose-dependent manner with an IC50 of
about 20 mM (Fig. 2A). Further analysis demonstrated that LJK-11
also induced apoptosis in A549 cells (Fig. 2B). The apoptosis, as
indicated by the cleavage of PARP, occurred 24 hours after LJK-
11 treatment (Fig. 2B).
We then analyzed the cell specificity of LJK-11 using human
tumor cell lines of different tissue origins, including the lung
adenocarcinoma cell line A549, cervical cancer cell line Hela,
gastrointestinal cancer cell line HGC-27, and breast cancer cell
line MDA-MB-453. Our data indicated that LJK-11 inhibited the
growth of A549, Hela, and HGC-27 equally, while had less effect
on MDA-MB-453 cells (Fig. 3). These results demonstrated that
LJK-11 inhibits growth of most of the tumor cells.
To explore the mechanism of the growth inhibition and cell death
effects of LJK-11 on tumor cells, we analyzed the expression and
phosphorylation of several major cell growth and survival signaling
proteins along the tyrosine kinase signaling pathway, including ERK,
JNK, and AKT. The results indicated that LJK-11 had no obvious
Figure 1. Chemical structure of LJK-11.
doi:10.1371/journal.pone.0010499.g001
Figure 2. Effect of LJK-11 on the growth and death of A549 cells. A. MTT assay of LJK-11 effects on cell growth. A549 cells were incubated
with indicated concentrations of LJK-11 for 48 hours. The effect on cell growth and death was examined by MTT assay. The cell viability is expressed
as a percentage of the compound-treated viable cells divided by the viable cells of the untreated control. The data are the means of triplicates 6SD.
B. PARP cleavage assay of LJK-11 effects on inducing cell apoptosis. A549 cells were treated with 50 mM for indicated time periods. The cell lysates
were resolved by SDS-PAGE and analyzed by Western bolt analysis using anti-PARP antibody. The cleaved PARP is indicated by the arrow. Anti-
tubulin antibody was used as a protein loading control.
doi:10.1371/journal.pone.0010499.g002
Quinazoline, Anti-Mitosis
PLoS ONE | www.plosone.org 2 May 2010 | Volume 5 | Issue 5 | e10499effect on the phosphorylation of JNK, but increased the phosphor-
ylation of ERK 1/2 and decreased the phosphorylation of AKT
(Fig. 4), suggesting that inhibition of the PI3K/AKT pathway may be
one of the mechanisms that responsible for the LJK-11-induced
growth arrest and/or cell death.
LJK-11 arrested cells at G2/M phase
We observed gradual accumulation of rounded cells, which
resemble the appearance of mitotic cells, after addition of LJK-
11. We therefore analyzed the effect of LJK-11 on cell cycle[21].
LJK-11 induced a dose-dependent G2/M arrest after 24 hours of
drug exposure. 88% of the cell population was blocked in G2/M
phase when they were exposed to 50 mM LJK-11 for 24 hours
(Fig. 5A and B).
To test whether the anti-mitotic activity of LJK-11was universal
to all tumor cells, we further analyzed the effect of LJK-11 on the
cell cycle progression of the MDA-MB-453 cells, which was
relatively insensitive to LJK-11 treatment in the MTT assay.
(Fig. 3). As shown in Figure 5, LJK-11 also effectively blocked the
MDA-MB-453 cells at G2/M phase (Fig. 5C and D). These data
clearly indicate that LJK is a mitotic blocker.
LJK-11 disrupted mitotic spindles in cells and inhibited
tubulin polymerization in vitro
Most of the anti-mitotic agents interact with microtubules[22].
The effect of LJK-11 on microtubule structure was then examined
by immuno-fluorescence microscopy using an a-tubulin antibody.
Normal control cells in metaphase displayed a bipolar mitotic
spindle. Condensed chromosomes lined up between the spindle
poles to form the metaphase plate (Fig. 6A). Cells exposed to LJK-
11 for 16 hours displayed disrupted appearance of mitotic spindles
(Fig. 6B). To compare the effect of LJK-11 with other mitotic
blockers, cells were treated with different concentrations of
nocodazole, taxol or colchicine for 16 hours. Taxol, a microtu-
bule-stabilizing agent, increased microtubules and induced multi-
polar spindles (Fig. 6E)[23]. Colchicine and nocodazole, two
microtubule depolymerizing agents[24,25], caused multipolar
mitotic spindle formation (Fig. 6C and D). LJK-11 (Fig. 6B) also
caused multipolar mitotic spindle formation, similar to that of
colchicines and nocodazole, suggesting that LJK-11 is a microtu-
bule depolymerizing agent. Further more, the microtubule
structure in interphase cells were also disrupted (Fig. 7), further
confirming that LJK-11 interacted with tubulin directly.
To confirm the above observation, we investigated the effect of
LJK-11 on tubulin polymerization using an in vitro tubulin
polymerization assay (Fig. 8). LJK-11 inhibited polymerization of
microtubules in a dose-dependent manner. Taken together, our
data indicate that LJK-11 is a microtubule assembly inhibitor.
To test whether LJK-11 is a reversible inhibitor, we incubated
the cells with LJK-11 for 20 hours and then washed out the LJK-
11 and incubated the cells for additional 18 hours. The LJK-11-
treated cells grew again after washing, suggesting that the LJK-11
treatment is reversible. One the contrary, the colchicines-treated
cells did not recover after washing (Fig. 9)
LJK-11 and colchicine acted synergistically to induce G2/
M arrest
To find out whether LJK-11 functions similarly to other known
anti-microtubule agents, we analyzed the effects of LJK-11 in
Figure 3. Effect of LJK-11 on the growth and death of different tumor cells. A549, Hela, HGC-27, or MDA-MB-453 cells were incubated with the
indicated concentrations of LJK-11 for 48 hours. The effect of LJK-11 on cell growth and death was evaluated by MTT assay. The cell viability is expressed as
a percentage of the compound-treated viable cells divided by the viable cells of the untreated control. The data are the means of triplicates 6SD.
doi:10.1371/journal.pone.0010499.g003
Figure 4. Effect of LJK-11 on tyrosine phosphorylation of
signaling proteins. A549 cells were treated with 50 mM LJK-11 for 6,
12, 24, or 36 hours. The cell lysates were resolved by SDS-PAGE and
analyzed by Western bolt analysis using antibodies as indicated.
Antibodies specific to the phosphorylated forms of the indicated
proteins are labeled with (-P).
doi:10.1371/journal.pone.0010499.g004
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PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10499Figure 5. Effects of LJK-11 on cell cycle distribution. A. Flow cytometry analysis of LJK-11-treated A549 tumor cells. A549 cells were incubated
with different concentrations of LJK-11 for 24 hours. The cells were then fixed and stained with PI, and analyzed by flow cytometry. B. Percentage of
cells in G2/M phase after 24 hours treatment with different concentrations of LJK-11. The data are the means of triplicates 6SD. C. Flow cytometry
analysis of LJK-11-treated MDA-MB-453 tumor cells. MDA-MB-453 cells were incubated with different concentrations of LJK-11 for 24 hours. The cells
were then fixed and stained with PI, and analyzed by flow cytometry. D. Percentage of cells in G2/M phase after 24 hours treatment with different
concentrations of LJK-11. The data are the representative of three independent experiments.
doi:10.1371/journal.pone.0010499.g005
Figure 6. Effects of LJK-11 on mitotic spindle formation. A549 cells were incubated on glass coverslips with different reagents for 16 hours,
and then fixed and stained with a-tubulin antibody to visualize microtubules (green) and with DAPI to visualize chromosomes (blue). The cells were
visualized by indirect immunofluorescent microscopy. A: control cells treated with equal volume of DMSO (0.1%). B: cells treated with 100 mM LJK-11.
C: cells treated with 5 nM nocodazole. D: cells treated with 100 nM colchicine. E: cells treated with 50 nM Taxol.
doi:10.1371/journal.pone.0010499.g006
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growth and death. We found that combination of LJK-11 and
colchicine synergistically increased the percentage of G2/M-
arrested cells (Fig. 10).The percentage of cells in G2/M after
incubation with the combination of the two drugs (76.864.3%)
was much greater than that of LJK-11 alone (22.365.5%) or
colchicine alone (14.261.9%) at the same concentration. The
Combination Index value (CI=0.6360.08, 95% confidence
interval) indicated that the combination of LJK-11 and colchicine
acted synergistically to block mitosis. On the contrary, combina-
tion of LJK-11 with two other microtubule depolimerizing agents,
nocodazole or vinblastine sulfate, had neither synergistic nor
additive effects (data not shown).
Discussion
LJK-11 is a novel compound and its structure is different from
that of colchicine, nocodazole, vinblastine, or taxol[26,27]. It was
identified from screening a series of growth inhibitory compounds.
It inhibits proliferation and induces apoptosis of different types of
tumor cell lines. We presented several lines of evidences to
demonstrate that LJK-11 blocked mitosis of tumor cells by
inhibiting microtubule polymerization.
The exact mechanism by which LJK-11 inhibits microtubule
polymerization is not completely understood. The in vitro analysis of
the effect of LJK-11 on microtubule polymerization suggests that
LJK-11 may interact directly with tubulin. Both microtubule-
stabilizing and microtubule–destabilizing agents cause formation of
abnormal mitotic spindle and inhibited mitotic progression[25,28].
The effect of LJK-11 likelyindicates inhibition of normal microtubule
dynamics and microtubule polymerization [29,30]. Visualization of
mitotic spindle with fluorescent microscopy indicated that LJK-11
caused multipolar mitotic spindles. The mode of action on inhibiting
microtubule polymerization and the effect on mitotic spindle
formation of LJK-11 resemblemost that of colchicines[31]. However,
the fact that LJK-11 acted synergistically with colchicine on blocking
mitosis suggests that LJK-11 may interact with a different site of
tubulin from that of colchicines[32–34]. Taken together, these data
suggest that LJK-11 is a new type of microtubule depolymerizing
agent and is different from colchicine.
In addition to its anti-mitosis activity, LJK-11 also induced
apoptosis of most of the tumor cells. To understand better the
mechanism of the LJK-11-induced apoptosis, we also analyzed the
effects of LJK-11 on phosphorylation/activation of several cell
growth and survival-related signaling proteins, including ERK1/
2., JNK, and AKT. LJK-11 had no obvious effect on the
phosphorylation of JNK, but increased the phosphorylation of
ERK1/2 and decreased the phosphorylation of AKT. The effects
of LJK-11 on JNK and ERK1/2 are also different from that of the
mitotic blockers colchicine, vinblastine, or taxol, all of which
increased phosphorylation of JNK while decreased phosphoryla-
tion of ERK1/2[35,36]. Although it is not clear what role the
ERK activation may play in the LJK-11-induced apoptosis, our
data suggest that LJK-11 has different effects on cellular signaling
system in comparison with other mitotic blockers and that
inhibition of AKT phosphorylation/activation may be the key
for LJK-11 to induce apoptosis of tumor cells. Under this notion, it
is interesting to note that the apoptosis-inducing activity of LJK-11
appeared to be selective comparing to its universal anti-mitosis
activity. Some of the tumor cells, such as MDA-MB-453, were
resistant to the LJK-11-induced cell death. Further investigation
into the correlation between the AKT activation and the sensitivity
to the LJK-11-induced apoptosis in various tumor cells will help to
evaluate its potential as an anti-cancer drug.
In summary, we have identified a new type of microtubule
depolymerizer and a mitotic blocker. Understanding of the
mechanism of LJK-11 on inhibiting microtubule polymerization
and induction of apoptosis of tumor cells and its differences from
other microtubule polymerization inhibitors will help us to design
better anti-cancer drugs.
Figure 7. Effects of LJK-11 on tubulin structure in non-mitotic cells. A549 cells were incubated on glass coverslips with (B) or without (A) LJK-
11 for 4 hours, and then fixed and stained with a-tubulin antibody to visualize microtubules (green) and with DAPI to visualize chromosomes (blue).
The cells were visualized by indirect immunofluorescent microscopy.
doi:10.1371/journal.pone.0010499.g007
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Chemical synthesis of compound LJK-11
LJK-11 (MW: 312.28) was synthesized via a straightforward six-
step synthetic route as reported previously[19,20], starting from
the commercially available 3-chloro-2-methyl aniline and employ-
ing Neimentowski synthesis as the key step. The final product was
characterized by HNMR, MS, and Elemental analyses. All other
chemicals were purchased from Sigma Chemical Co.
Cell culture and reagents
Human lung adenocarcinoma cell line A549, cervical cancer
cell line Hela, and breast cancer cell line MDA-MB-453 were
purchased from ATCC; gastrointestinal cell line HGC-27 was
provided by the Fourth Military Medical University of China.
A549 cells were cultured in RPMI 1640 medium supplemented
with 10% FBS; other cell lines were cultured in DMEM medium
supplemented with 10% FBS.
MTT assay
Cells were seeded in a 96-well plate (5610
3 cells/well) and
cultured overnight, then treated with various concentrations of
LJK-11 and incubated for additional 48 hours. The MTT (3-(4, 5-
dimethylthiazol–2-yl) -2, 5-diphenyl tetrazolium bromide) assay
was performed by adding 20 ml of MTT solution (5 mg/ml, Sigma
Chemical Co.) to each well and incubated for 3 hours at 37uC.
The supernatant was aspirated, and the MTT-formazan crystals
formed by metabolically viable cells were dissolved in 150 mlo f
DMSO. The absorbance was measured by a microplate reader at
a wavelength of 570 nm.
Flow Cytometry analysis
The cells were harvested and washed with PBS, resuspended in
1 ml of ice-cold 75% ethanol. After being left to stand overnight,
cell pellets were collected by centrifugation, resuspended in 500 ml
of hypotonic buffer (0.5% Triton X-100 in PBS and 0.5 mg/ml
RNase), and incubated at 37uC for 30 min. Then 25 mlo f
Figure 8. Effect of LJK-11 on tubulin polymerization. Effects of LJK-11 (250 mM), colchicines (10 mM), nocodazole (10 mM), or Taxol (10 mM) on
bovine brain tubulin polymerization were measured turbidimetrically(A). Effects of 1 mM, 5 mM, 25 mM, 100 mM, 200 mM LJK-11 on bovine brain
tubulin polymerization were also measured. Changes in absorbance at 340 nm (A340) were measured and plotted as a function of time(B).
doi:10.1371/journal.pone.0010499.g008
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was allowed to stand on ice for 1 hour. Fluorescence emitted from
the propidium iodide-DNA complex was quantitated after
excitation of the fluorescent dye by FAC-Scan cytometry. The
histogram of DNA distribution was modeled as a sum of G1, G2/
M, S phase, and an sub-G1 population, by using ModFitLT
software.
Immunofluorescence microscopy
After culturing for 48 hours on cover-slips, A549 cells were
incubated with drugs at various concentrations for 16 hours. Cells
were then fixed. After blocking, cells were incubated with mouse
monoclonal a-tubulin antibody for 2 hours at 37uC. The
secondary antibody, Fluorescein (FITC)-conjugated affinipure
goat anti-mouse IgG (H+L), was added and incubated for 1 hour.
Chromosomes were stained with 1 mg/ml DAPI in PBS. After
washing with PBS, the slides were mounted and sealed.
Fluorescence images were captured by using Leica TCS SP2 laser
confocal microscope.
Western Blot Analysis
Cells were lysed in the ice-cold cell lysis buffer (PH 7.6)
containing 0.5 mM dithiothreitol, 0.2 mM EDTA, 20 mM
HEPES, 2.5 mM MgCl2,75 mM NaCl, 0.1 mM Na3VO4,
50 mM NaF, and 0.1% Triton X-100. The protease inhibitors
including 1 mg/ml aprotinin, 0.5 mg/ml leupeptin, and 100 mg/ml
4-(2-aminoethyl)-benzenesulfonyl fluoride were added to the cell
suspension. The cell extracts were gently rotated at 4uC for
30 min. After centrifugation, the pellets were discarded. Equal
amounts of proteins were subjected to 8–10% SDS-PAGE. After
transfer of proteins onto nitrocellulose membranes, they were
hybridized with various antibodies according to the instructions
provided by the manufacturers.
In vitro tubulin polymerization assay
The assay was essentially performed according to Ching-Chuan
Kuo et al [37]. Briefly, the sample (100 ml of 3 mg/ml tubulin
proteins) in TP buffer (100 mM PIPES, pH 6.9, 2 mM MgCl2,
1 mM GTP, and 15% glycerol) was placed in 96-well microtiter
plates in the presence of test agents. Mixtures were warmed to
37uC and the increase in absorbance was measured at 340 nm in
TECAN Genois Pro Microplate Reader and recorded every 9
seconds for 1 hour.
Analysis of drug synergism
The Combination Index (CI) was calculated to determine whether
the drugs interacted synergistically, additively, or antagonistically
[14]. The CI is calculated by the following equation: CI=(D)1/
(Dx)1+(D)2/(Dx)2+(D)16(D)2/(Dx)16(Dx)2, in which (D)1 is the
concentration of a drug necessary to achieve a particular effect in
the combination; (Dx)1 is the concentration of the same drug that will
produce the identical level of effect by itself; (D)2 is the concentration
of the second drug that will produce a particular effect in the
combination; and (Dx)2 is the concentration of the second drug,
which will produce the same level of effect by itself. CI.1i n d i c a t e s
antagonism, CI ,1indicates synergy, and CI=1 indicates additivity
[38]. Two independent experiments were performed to obtain the
CI. In the first experiment, (D)1=10mM, (Dx)1=25.84mM,
(D)2=20nM,(Dx) 2=92.79 nM, CI=0.686; in the second experi-
Figure 9. Reversibility of LJK-11 treatment. Hela cells were incubated with 50 mM LJK-11 or 20 nM colchicine for 20 hours (A) and then the
compound-containing media were removed, the cells were washed with fresh media, and the cells were incubated in new compound-free media for
additional 18 hours (B). The pictures were taken using a light microscope.
doi:10.1371/journal.pone.0010499.g009
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88.283 nM,CI=0.572. The average CI=0.6360.08.
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